Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Subscribe To Our Newsletter & Stay Updated